Related Experiment Video
Updated: Apr 21, 2026
10:26
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
28.5K
Resequencing microarray technology for genotyping human papillomavirus in cervical smears
Nicolas Berthet1, Michael Falguières2, Claudia Filippone1
1Institut Pasteur, Epidémiologie et Physiopathologie des Virus Oncogènes, 75724 Paris Cedex 15, France; Centre National de la Recherche Scientifique, UMR 3569, 75724 Paris Cedex 15, France.
Plos One
|November 11, 2014
Summary
This study shows reconstructed ancestral sequences (RASs) improve human papillomavirus (HPV) detection and genotyping. This resequencing microarray method is valuable for epidemiological studies and monitoring HPV distribution.
Area of Science:
- Virology
- Genetics
- Molecular Diagnostics
Background:
- Over 40 alpha genus human papillomaviruses (HPVs) cause frequent sexually transmitted infections.
- Alpha HPVs are linked to condylomas, anogenital intraepithelial neoplasia, and at least 18 cause anogenital carcinomas.
Purpose of the Study:
- To evaluate a resequencing microarray for detecting and genotyping clinically significant alpha HPVs.
- To assess the utility of reconstructed ancestral sequences (RASs) for HPV genotyping.
Main Methods:
- Utilized cloned HPV DNA and reconstructed ancestral sequences (RASs) for microarray design.
- Tested the microarray's performance by genotyping 40 cervical smear samples previously analyzed with the PapilloCheck kit.
Main Results:
- The resequencing microarray showed 70% concordance and 30% compatibility with the commercial kit.
- RASs effectively detected and identified single or multiple HPV infections in clinical samples.
- Combining RASs with homonym sequences enhanced genotyping accuracy in cases of multiple infections.
Conclusions:
- Demonstrated the diagnostic potential of resequencing technology for HPV genotyping.
- Highlighted the value of this approach for epidemiological surveillance and monitoring HPV in the post-vaccination era.
